Course Detail

HIV Elite Controllers and What We’ve Learned from Them

Details

Published Date: 01/15/2024

Expiration Date: 12/12/2026

CE Credit: CME:1

Description

Soon after HIV was discovered, clinicians and researchers became fascinated by a small group of people with HIV who did not progress even though they were not taking antiretroviral therapy (ART). Initially termed long-term non-progressors, some of these individuals maintain undetectable HIV RNA without taking ART and are called HIV elite controllers. In this talk, Dr. Gandhi will talk about how best to diagnose elite controllers in the era of early ART initiation and summarize the factors associated with HIV control. He will talk about the price of this control – namely immune activation and inflammation – in some elite controllers and why ART may be warranted.

Presenter(s)

Rajesh T. Gandhi,MD

Rajesh T. Gandhi, MD is Professor of Medicine at Harvard Medical School, and the Director of HIV Clinical Services and Education at Massachusetts General Hospital (MGH). Dr. Gandhi is the site leader of the MGH AIDS Clinical Research Site in the AIDS Clinical Trials Group (ACTG). He is also the Co-Director of the Harvard University Center for AIDS Research (CFAR). Dr. Gandhi is a member of the NIH Covid-19 Treatment Guidelines Panel and the Infectious Diseases Society of America (IDSA) Covid-19 Treatment Guidelines Panel. He is also a scientific member of the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, and the International Antiviral Society-USA Panel on Antiretroviral Drugs for Treatment and Prevention of HIV in Adults. Dr. Gandhi is a Deputy Editor of NEJM Journal Watch Infectious Diseases and NEJM Journal Watch HIV/AIDS. Dr. Gandhi graduated from Harvard Medical School, completed his medical residency and chief residency at Brigham and Women’s Hospital, and his infectious diseases fellowship training at Johns Hopkins Hospital.

Learning Objectives

Be aware of data on antiretroviral therapy in people with HIV (PWH) who are elite controllers.
Understand how HIV elite control may inform new cure strategies
Know recent information on HIV reservoir decay in PWH who are receiving antiretroviral therapy.

Continuing Education Credit Information

Learn more and Enroll